Drug Trial Radar · NCT00653224
A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic Rhinitis
Last checked: Nov 20, 2026Latest source record: Aug 31, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
580
Actual
Start
Apr 2008
Primary completion
Jul 2008
Study completion Jul 2008
Sponsor
- Lead sponsor
- UCB PharmaUCB
- Sponsor type
- Industry
- First posted
- Apr 4, 2008
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study objective is to investigate the efficacy of levocetirizine in reducing symptoms associated with seasonal allergic rhinitis and in improving rhinitis-related Quality of Life.
Conditions
- Seasonal Allergic Rhinitis
Interventions
levocetirizine dihydrochlorideDrug
5 mg daily (oral tablet) for 14 days
placeboDrug
0 mg daily (matching oral tablet) for 14 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean 24-hour Reflective Total 5 Symptoms Score (T5SS) Over the Total Treatment Period (14 Days)Time frame: Over the total treatment period (14 days)
Locations
38 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Tucson, Arizona
Site not named
Los Angeles, California
Site not named
Sacramento, California
Site not named
San Francisco, California
Site not named
San Jose, California
Site not named
Colorado Springs, Colorado
Site not named
Denver, Colorado
Site not named
Miami, Florida
Site not named
Atlanta, Georgia
Site not named
Gainesville, Georgia
Site not named
Lawrenceville, Georgia
Site not named
Stockbridge, Georgia
Site not named
Normal, Illinois
Site not named
Louisville, Kentucky
Site not named
Harvard, Massachusetts
Site not named
North Dartmouth, Massachusetts
Site not named
Novi, Michigan
Site not named
Minneapolis, Minnesota
Site not named
Berlin, New Jersey
Site not named
Skillman, New Jersey
Site not named
Verona, New Jersey
Site not named
Rochester, New York
Site not named
Asheville, North Carolina
Site not named
Charlotte, North Carolina
Site not named
Wilmington, North Carolina
Site not named
Cincinnati, Ohio
Site not named
Edmond, Oklahoma
Site not named
Oklahoma City, Oklahoma
Site not named
Portland, Oregon
Site not named
Pittsburgh, Pennsylvania
Site not named
Upland, Pennsylvania
Site not named
Lincoln, Rhode Island
Site not named
Germantown, Tennessee
Site not named
San Antonio, Texas
Site not named
Salt Lake City, Utah
Site not named
South Burlington, Vermont
Site not named
Arlington, Virginia
Site not named
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.